MA28946B1 - Utilisation de 4-(4-methylpiperazin-1-ylmethyl) -n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide pour inhiber le recepteur c-fms de la tyrosine kinase - Google Patents

Utilisation de 4-(4-methylpiperazin-1-ylmethyl) -n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide pour inhiber le recepteur c-fms de la tyrosine kinase

Info

Publication number
MA28946B1
MA28946B1 MA29848A MA29848A MA28946B1 MA 28946 B1 MA28946 B1 MA 28946B1 MA 29848 A MA29848 A MA 29848A MA 29848 A MA29848 A MA 29848A MA 28946 B1 MA28946 B1 MA 28946B1
Authority
MA
Morocco
Prior art keywords
methylpiperazin
ylamino
benzamide
pyrimidin
ylmethyl
Prior art date
Application number
MA29848A
Other languages
English (en)
Inventor
Andrea Louis Dewar
Timothy Peter Hughes
Alan Bruce Lyons
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of MA28946B1 publication Critical patent/MA28946B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA29848A 2004-10-18 2007-04-25 Utilisation de 4-(4-methylpiperazin-1-ylmethyl) -n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide pour inhiber le recepteur c-fms de la tyrosine kinase MA28946B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61974404P 2004-10-18 2004-10-18

Publications (1)

Publication Number Publication Date
MA28946B1 true MA28946B1 (fr) 2007-10-01

Family

ID=36202610

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29848A MA28946B1 (fr) 2004-10-18 2007-04-25 Utilisation de 4-(4-methylpiperazin-1-ylmethyl) -n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide pour inhiber le recepteur c-fms de la tyrosine kinase

Country Status (19)

Country Link
US (1) US20080255139A1 (fr)
EP (1) EP1804800B1 (fr)
JP (1) JP2008516898A (fr)
KR (1) KR20070083705A (fr)
CN (1) CN101035535A (fr)
AT (1) ATE492277T1 (fr)
AU (1) AU2005297321A1 (fr)
BR (1) BRPI0517083A (fr)
CA (1) CA2580976A1 (fr)
DE (1) DE602005025514D1 (fr)
IL (1) IL182419A0 (fr)
MA (1) MA28946B1 (fr)
MX (1) MX2007004660A (fr)
NO (1) NO20072501L (fr)
NZ (1) NZ554009A (fr)
RU (1) RU2007118420A (fr)
TN (1) TNSN07141A1 (fr)
WO (1) WO2006042362A1 (fr)
ZA (1) ZA200702316B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008318656A1 (en) * 2007-10-31 2009-05-07 Janssen Pharmaceutica N.V. Biomarker for assessing response to FMS treatment
EP3246046A4 (fr) * 2015-01-13 2018-12-05 Kyoto University Agent pour la prévention et/ou le traitement de la sclérose latérale amyotrophique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) * 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
CA2446939C (fr) * 2001-05-16 2005-08-02 Matthias Stein-Gerlach Derives de pyridylpyrimidine utilises comme composes actifs contre des infections et des maladies a prions
WO2004026930A2 (fr) * 2002-06-26 2004-04-01 The Ohio State University Research Foundation Composes organiques

Also Published As

Publication number Publication date
RU2007118420A (ru) 2008-11-27
MX2007004660A (es) 2007-10-17
TNSN07141A1 (en) 2008-11-21
KR20070083705A (ko) 2007-08-24
ATE492277T1 (de) 2011-01-15
DE602005025514D1 (de) 2011-02-03
EP1804800A4 (fr) 2008-03-19
IL182419A0 (en) 2007-09-20
US20080255139A1 (en) 2008-10-16
CA2580976A1 (fr) 2006-04-27
EP1804800A1 (fr) 2007-07-11
WO2006042362A1 (fr) 2006-04-27
ZA200702316B (en) 2008-09-25
AU2005297321A1 (en) 2006-04-27
NO20072501L (no) 2007-05-15
CN101035535A (zh) 2007-09-12
EP1804800B1 (fr) 2010-12-22
JP2008516898A (ja) 2008-05-22
BRPI0517083A (pt) 2008-09-30
NZ554009A (en) 2010-09-30

Similar Documents

Publication Publication Date Title
AR112118A2 (es) Inhibidores de pi-3 quinasa
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
MX391723B (es) Composiciones de forma de dosificacion que comprenden un inhibidor de tirosina cinasa de bruton.
NO20075624L (no) Nye histamin H3-reseptorligander og deres terapeutiske anvendelser
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
NO20075022L (no) (7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav
EA201070366A1 (ru) 3-метил-2-((2s)-2-(4-(3-метил-1,2,4-оксадиазол-5-ил)фенил)морфолино)-6-(пиримидин-4-ил)пиримидин-4(3н)-он в качестве ингибитора тау-протеинкиназы
WO2008059551A3 (fr) Procédé de préparation d'imatinib et d'intermédiaires correspondants
NZ590177A (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
MA35636B1 (fr) Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide
IL182419A0 (en) Use of 4- (4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms
EP2126129A4 (fr) Protéine kinase 1 associée à l'apoptose (dapk1) et ses utilisations pour le traitement de la leucémie lymphocytique chronique
IL162983A (en) Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
HRP20100265T1 (hr) Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti
JP2008542390A5 (fr)
RU2015120692A (ru) Производное 6-оксо-1,6-дигидро-пиридизина для применения в лечении гепатоцеллюлярной карциномы (гцк)
NO20056188L (no) Anvendelse av en c-Abl-, PDGF-R- eller c-kit-tyrosinkinaseinhibitor for behandling av diabetes
RU2020127993A (ru) Терапевтическое средство для лечения гепатоцеллюлярной карциномы
JP2008516898A5 (fr)